Profile: Assertio Therapeutics Inc (ASRT.OQ)
17 May 2019
Assertio Therapeutics, Inc., incorporated on August 7, 1995, is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium).
Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks. The Company’s Zipsor (diclofenac potassium) liquid filled capsules are used for the treatment of mild to moderate acute pain. In collaboration with Ironwood Pharmaceuticals, Inc., the Company offers IW-3718, which is under evaluation for refractory gastroesophageal reflux disease (GERD).
The Company competes with Insys Therapeutics, Inc., Sentynl Therapeutics Inc., Collegium Pharmaceutical, Inc., Mallinckrodt Inc., Endo Pharmaceuticals, Inc., Pfizer, Inc., Arbor Pharmaceuticals and Teva.
Assertio Therapeutics Inc
100 Saunders Rd Ste 300
LAKE FOREST IL 60045-2508